Prof. James Larkin

Prof. James Larkin is one of the United Kingdom's most prominent medical oncologists, practicing at the Royal Marsden Hospital in London — the world's first cancer hospital and a globally recognized center for cancer research and treatment. With over 25 years of clinical and research experience, Prof. Larkin has established himself as an international authority in the treatment of melanoma and renal cell carcinoma (kidney cancer), particularly through the development and application of immunotherapy and targeted therapy. He has been a principal investigator in numerous landmark clinical trials that have reshaped the global standard of care for advanced melanoma, including pivotal combination immunotherapy studies. His dual role as a clinician and scientist means patients benefit from access to both cutting-edge experimental treatments and rigorous evidence-based clinical care. He holds a PhD in cancer immunology and is a Fellow of the Royal College of Physicians.

Prof. Larkin holds a medical degree (MBBS) from University College London, one of the UK's leading research-intensive universities. He subsequently completed his clinical oncology training through the NHS and the Royal Marsden, developing deep expertise in the management of solid tumours. He earned a PhD focused on the immunology of renal cell carcinoma, reflecting early interest in cancer-immune interaction at a time when immunotherapy was still an emerging field. His academic credentials were further consolidated by election as Fellow of the Royal College of Physicians (FRCP), the UK's foremost professional body for internal medicine and its subspecialties. His postgraduate training combined rigorous NHS clinical apprenticeship with translational cancer research, a combination that directly shaped his subsequent contributions to melanoma treatment innovation.

Prof. Larkin's clinical practice is concentrated in advanced melanoma and renal cell carcinoma, with particular expertise in immunotherapy using checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 agents (nivolumab, pembrolizumab, ipilimumab). He has contributed to the development of combination immunotherapy regimens that have transformed survival outcomes in metastatic melanoma. In targeted therapy, he works with BRAF/MEK inhibitor combinations for BRAF-mutated melanoma, individualizing treatment selection based on molecular profiling. He is an established clinical trialist who has led phase I, II, and III studies at the Royal Marsden, providing patients access to investigational agents not yet commercially available. His expertise extends to managing immune-related adverse events from immunotherapy — a critical skill given the complexity of next-generation oncological care.

The Royal Marsden Hospital operates a dedicated International Patients service that facilitates treatment for patients travelling from overseas for cancer care in London. The hospital's international office assists with referral coordination, medical record review, treatment cost estimates, and liaison with international insurance providers. As a world-leading cancer centre, the Royal Marsden attracts patients with complex or rare malignancies from across Europe, the Middle East, and beyond. International patients seeking second opinions on melanoma, kidney cancer, or clinical trial eligibility can request a structured review with Prof. Larkin's team. London's global connectivity and the Royal Marsden's international reputation make it a natural destination for patients seeking oncology expertise outside their home country.

Prof. Larkin is internationally recognized for his contributions to oncology, having co-authored research that established combination immunotherapy as a standard-of-care for advanced melanoma. His clinical trial work has been presented at major international oncology congresses including ASCO, ESMO, and AACR. He has received research funding from Cancer Research UK, the Wellcome Trust, and industry partners for melanoma and kidney cancer programs. His election as FRCP reflects sustained professional achievement. Within the Royal Marsden, he is recognized as one of the institution's leading clinician-scientists, contributing to its global standing as a center of excellence in medical oncology and cancer immunotherapy research.